Loading…
← CockpitCompetitor Analysis › 2228.HK XtalPi Holdings LimitedOpen in the cockpit ↗

XtalPi Holdings Limited2228.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese AI and quantum-physics drug-discovery platform that predicts molecular structures for pharma and materials clients.

≈ A Chinese Schrödinger/Recursion PharmaceuticalsMomentum weak 26
Mkt cap
$2.87B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$30.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-35.9 pp
WACC 16.4%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$5.39
1D+1.3%
1W-15.3%
1M-11.4%
3M-25.4%
6M-34.1%
YTD-43.0%
1Y-51.5%
ATR %6.2%
52w lowhigh62.2% off high

What XtalPi does

Chinese AI and quantum-physics drug-discovery platform that predicts molecular structures for pharma and materials clients.

Earns fees for running discovery projects for drug companies, often a mix of up-front payments, milestones and later royalties, plus sales of automated laboratory systems built on its robotics. It listed in Hong Kong in 2024 under rules for technology companies not yet profitable (Chapter 18C).

In one line: A Chinese Schrödinger/Recursion Pharmaceuticals.

Products and services

  • AI-driven drug discovery platform
  • Quantum physics molecular simulation
  • New materials discovery
  • Robotics-enabled digital labs

Customers

  • Global pharma & biotech companies
  • Materials/chemical companies

Where it sits in the supply chain

  • Drug discovery technology
  • AI/computational chemistry platform
  • Discovery services & co-development

What could go right

  • Pharma AI-discovery partnership growth
  • Expansion into materials science

What could go wrong

  • Unproven long-term drug-discovery hit rate
  • Partner/licensing revenue concentration

Moat: narrow (IP / patents, data, process know-how). Proprietary AI+quantum simulation platform and data, but competes with a growing AI-drug-discovery field.

Headquarters: Shenzhen, China · Founded: 2014 · Employees: 1,254

Named competitors

XtalPi at a glance

Size XtalPi (2228.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $2.87B, the 338th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.39 on 18 Nov 2026.

Performance Over six months the shares fell 34.1%, against -2.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 3.9% over the last twelve months (peer median +12.3%); the operating margin is -127.5% (peer median 5.2%).

Valuation It trades at 21.3× enterprise value to sales against a peer median of 6.0× (4th most expensive of 18).

Capital Return on invested capital runs 35.9 points below its cost of capital (16.4% WACC).

Credit XtalPi has 1 bond outstanding ($365M).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 982228.HK 68
Six months, rebased to 100: XtalPi against the median of its 20 peers (local-currency closes).

XtalPi financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$761MHK$870MHK$289MHK$193MHK$155M
Revenue growth—+201%+50%+24%—
Gross profitHK$317MHK$481M-HK$17.4M-HK$79.9M-HK$2.06M
EBITDA-HK$829M-HK$389M-HK$700M-HK$740M-HK$546M
Net income-HK$242MHK$134M-HK$1.64B-HK$2.12B-HK$1.67B
Free cash flow-HK$424M-HK$229M-HK$516M-HK$616M-HK$685M
Capital expenditureHK$124MHK$84.3MHK$67.1MHK$107MHK$217M
Total debtn/aHK$494MHK$158MHK$12.2BHK$10.6B

Quarterly statements and history in the cockpit →

XtalPi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%BAVARUBICONDNLI9688DYNTLXADMA028300MBXXERSXNCRVIRP688278ELVN3001426919IOVA2228.HK6-month return →1-month return →
Up and to the right = strong over both horizons. XtalPi is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%+50%0×2,000×4,000×6,000×BAVARUBICON9688TLXADMA6887XERS0020073001426919IOVA2228.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. XtalPi is the large dot.

XtalPi competitors and peer comparison

Head to head with its named competitors (2228.HK vs SDGR vs RXRX vs ABSI)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
XtalPi 2228.HK$2.87B-34%+4%-127%21.3×n/a
Schrodinger SDGR$2.04B+127%+5%-50%6.6×n/a
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%18.8×n/a
Absci ABSI$1.41B+65%-47%-9,155%835.7×n/a

How XtalPi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

XtalPi against its 20 peers (data as of 18 Nov 2026)
Measure2228.HKPeer medianRank in peer set
1-month return-11.4%-3.3%5th lowest of 21
6-month return-34.1%-2.0%2nd lowest of 21
Distance from 52-week high-62.2%-29.3%lowest of 21
Revenue growth (TTM)+3.9%+12.3%7th lowest of 17
Operating margin-127.5%5.2%3rd lowest of 18
EV / Sales21.3×6.0×4th most expensive of 18
ROIC minus cost of capital-35.9 pp-5.7 pp5th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%

XtalPi bonds and credit

XtalPi has 1 bond outstanding with $365M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are XtalPi's main competitors?
Named competitors: Schrödinger (SDGR), Recursion Pharmaceuticals (RXRX), Absci (ABSI). The cockpit's measured peer set (industry) also includes Bavarian Nordic A/S (BAVA.CO), Rubicon Research (RUBICON.NS), Denali Therapeutics (DNLI), Zai Lab (9688.HK), Dyne Therapeutics (DYN), Telix Pharmaceuticals (TLX.AX).
Is XtalPi expensive compared with its peers?
On ev / sales it trades at 21.3× against a peer median of 6.0×, 4th most expensive of 18 in its peer set.
How has XtalPi stock performed?
Over six months to 18 Nov 2026 the shares returned -34.1% against -2.0% for the median peer; over one year -51.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.